HomeTechTelecomAbbvie (ABBV) To Acquire Immunogen (IMGN)

Abbvie (ABBV) To Acquire Immunogen (IMGN)

Abbvie (ABBV) is to acquire Immunogen (IMGN). Jenny Horne discusses this Biotech deal as the transaction values IMGN at $10.1B. ABBV is to acquire outstanding shares of IMGN for $31.26 per share in cash. This deal is expected to close in the middle of 2024 and the proposed transaction is expected to be accretive to EPS beginning in 2027. Tune in to find out more about the stock market today.

Market On Close

30 Nov 2023

SHARE

ON AIR
education
6:00 pm
Schwab 2026 Outlook
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
ON AIR
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor